NEW YORK (TheStreet) -- CHANGE IN RATINGS
athenahealth was initiated with a neutral rating at Sterne Agee. $84 price target. Valuation is fair, Sterne Agee said.
Audience was initiated with a hold rating at TheStreet Ratings.
Biogen Idec was downgraded at Citigroup to neutral from buy. Price target is $236. There is risk that regulatory data protection for the company's flagship MS drug, Tecfidera, is limiting valuation, Citi said.
Bob Evans Farms was initiated with an overweight rating and $57 price target at Oppenheimer. Both the restaurant and grocery businesses are emerging from transformational initiatives, improving performance, Oppenheimer said.
Calumet Specialty Products was initiated with an outperform rating and $40 price target at Credit Suisse. Geographical and product diversity should provide solid distribution growth, Credit Suisse said.
Gulfport Energy coverage was reinstated at Credit Suisse with an outperform rating and $72 price target. Additional Utica inventory and a quicker than anticipated ramp to a seven-rig program will drive upside, Credit Suisse said.
Allscripts Healthcare Solutions was initiated with a buy rating at Sterne Agee. $17 price target. In the third inning of a long-term turnaround, Sterne Agee said.
Lakes Entertainment was downgraded to hold at TheStreet Ratings.
Ocean Rig was downgraded at Credit Suisse to neutral from outperform. Upside is limited given the stock's recent run, even as management returns cash to shareholders, Credit Suisse said. Price target is $19.
PAREXEL was initiated with a neutral rating at Sterne Agee. $44 price target. Successfully climbed PIII CRO market share ladder, Sterne Agee said.
Boston Beer was upgraded at Goldman Sachs to neutral from sell. $162 target price. Near-term volume upside potential, Goldman said.
Texas Roadhouse was initiated with a buy rating at Bank of America/Merrill Lynch. $28 price target. Well-established brand with attractive valuation, BofA/Merrill said.
STOCK COMMENTS/EPS CHANGES
Aegerion Pharmaceuticals price target was raised to $88 at J.P. Morgan. Encouraging physician feedback and the recent approval recommendation for Lojuxta have improved the valuation outlook, J.P. Morgan said.
Airgas estimates were reduced at Jefferies. Slow start to the year and weak construction demand, said Jefferies.
Cardinal Health price target was raised at Credit Suisse to $55. Contract changes, acquisitions and the evolution of drug distribution environment should be priced in to the stock, Credit Suisse said.
Cytec Industries estimates were raised at Jefferies. Reflects a faster share buyback, said Jefferies.
Macy's price target was raised of Bank of America/Merrill Lynch to $55. Analyst day highlights long-term growth opportunities, BofA/Merrill said. Reiterate Buy rating.
Navistar price target and estimates were reduced at UBS. Reflect the second-quarter miss and continued warranty expenses, UBS said. Price target decreased to $35.
Spectra Energy price target was raised at Deutsche Bank to $36. The company is pursuing the dropdown of all of its U.S. Transmission and Storage assets, said Deutsche Bank.
Tesoro price target and estimates were raised at J.P. Morgan to reflect the Carson refinery acquisition and Bakken intake, said J.P. Morgan. Price target goes to $65.
Ulta estimates were raised at Oppenheimer to reflect the better-than-expected first-quarter results, said Oppenheimer.
>To submit a news tip, email: firstname.lastname@example.org.